FMP
NASDAQ
0.91 USD
0.041 (4.51%)
Mr. Christopher A. Posner
Healthcare
Biotechnology
https://www.caratherapeutics.com
NASDAQ
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and ...
0001346830
US1407551092
140755109
4 Stamford Plaza
203 406 3700
US
55
Jan 31, 2014
0001346830
NASDAQ
Biotechnology
Healthcare
140755109
US1407551092
US
0.91
0.69
749.26k
49.74M
-
0.5-5.2
11.05
-
-
-
-
-0.42
-
https://www.caratherapeutics.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.